Shilpa Medicare Limited (BOM: 530549)
India
· Delayed Price · Currency is INR | Market Cap | 73.21B |
| Revenue (ttm) | 11.84B |
| Net Income (ttm) | 447.57M |
| Shares Out | 86.80M |
| EPS (ttm) | 4.98 |
| PE Ratio | 169.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,490 |
| Open | 832.50 |
| Previous Close | 831.90 |
| Day's Range | 830.60 - 855.75 |
| 52-Week Range | 296.45 - 855.75 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatini... [Read more]
Financial Performance
Financial StatementsNews
Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection
Following the company’s statement that the U.S. Food and Drug Administration (FDA) has approved its Bortezomib injection under New Drug Application (NDA) 212782, Shilpa Medicare Ltd.’s stock price inc...
Shilpa Medicare surges over 5% on USFDA approval for Bortezomib Injection
Shilpa Medicare Ltd. has seen its stock price surge by 5.1% or ₹37.30 to trade at ₹768.85 on the National Stock Exchange (NSE) following the company’s announcement of receiving U.S. Food and Drug Admi...
Shilpa Medicare gets USFDA approval for Bortezomib Injection
Shilpa Medicare Ltd has recently informed the exchanges that the USFDA has approved its second NDA [505(b)(2)], injectable product, Bortezomib Injection. Bortezomib Injection is approved for subcutane...
Shilpa Medicare reports successful outcome of Phase 3 studies of SMLNUD07 – NorUDCA
Shilpa Medicare has recently announced that it successfully completed phase-3 clinical studies on its novel productSMLNUD07 – Nor Ursodeoxycholic Acid (NorUDCA) tablets, which is likely to change the ...